Cancer-specific ligand-receptor interactions

E. Kluza, G.J. Strijkers, R.G.H. Beets-Tan, K. Nicolay

Research output: Chapter in Book/Report/Conference proceedingChapterAcademicpeer-review

2 Downloads (Pure)

Abstract

The concept of cancer targeting, which exploits the abundance of specific molecular epitopes on cancer cells, has been proposed as a strategy to enhance the efficacy and specificity of cancer therapy and diagnostics. Although many promising results have been obtained with this approach, the research experience of the last decades demonstrates clearly the challenges that the clinical application of cancer-targeted approaches faces. This can be attributed to both the complexity of targeted probe-cell interactions as well as the multitude of additional factors, which influence the efficacy of the targeting process. The aim of this chapter is to address the key steps involved in the cellular pathway of ligand-functionalized probes for cancer targeting. Special attention is given to nanoparticulate delivery systems as the most commonly exploited formulations for cancer targeting. Their interaction with target cells is initiated by ligand binding to the cell surface receptor, which is frequently followed by endocytosis of ligand-receptor complex and, in the final phase, by lysosomal degradation. All the aforementioned processes are presented in view of the pathophysiological and molecular features of the biological system as well as the physicochemical and biological properties of targeted probes. Importantly, we discuss the implications of these intracellular events for the therapeutic activity and diagnostic capabilities of targeted agents.

Original languageEnglish
Title of host publicationCancer Targeted Drug Delivery
Subtitle of host publicationAn Elusive Dream
EditorsYou Han Bae, Randall J. Mrsny, Kinam Park
Place of PublicationNew York
PublisherSpringer
Pages461-507
Number of pages47
ISBN (Electronic)978-1-4614-7876-8
ISBN (Print)978-1-4614-7875-1
DOIs
Publication statusPublished - 1 Jul 2013

Fingerprint

Ligands
Neoplasms
Cell Surface Receptors
Endocytosis
Cell Communication
Epitopes
Therapeutics
Research

Cite this

Kluza, E., Strijkers, G. J., Beets-Tan, R. G. H., & Nicolay, K. (2013). Cancer-specific ligand-receptor interactions. In Y. H. Bae, R. J. Mrsny, & K. Park (Eds.), Cancer Targeted Drug Delivery: An Elusive Dream (pp. 461-507). New York: Springer. https://doi.org/10.1007/978-1-4614-7876-8_18
Kluza, E. ; Strijkers, G.J. ; Beets-Tan, R.G.H. ; Nicolay, K. / Cancer-specific ligand-receptor interactions. Cancer Targeted Drug Delivery: An Elusive Dream. editor / You Han Bae ; Randall J. Mrsny ; Kinam Park. New York : Springer, 2013. pp. 461-507
@inbook{1e2953a4edd44b73bea2d0f41b05833c,
title = "Cancer-specific ligand-receptor interactions",
abstract = "The concept of cancer targeting, which exploits the abundance of specific molecular epitopes on cancer cells, has been proposed as a strategy to enhance the efficacy and specificity of cancer therapy and diagnostics. Although many promising results have been obtained with this approach, the research experience of the last decades demonstrates clearly the challenges that the clinical application of cancer-targeted approaches faces. This can be attributed to both the complexity of targeted probe-cell interactions as well as the multitude of additional factors, which influence the efficacy of the targeting process. The aim of this chapter is to address the key steps involved in the cellular pathway of ligand-functionalized probes for cancer targeting. Special attention is given to nanoparticulate delivery systems as the most commonly exploited formulations for cancer targeting. Their interaction with target cells is initiated by ligand binding to the cell surface receptor, which is frequently followed by endocytosis of ligand-receptor complex and, in the final phase, by lysosomal degradation. All the aforementioned processes are presented in view of the pathophysiological and molecular features of the biological system as well as the physicochemical and biological properties of targeted probes. Importantly, we discuss the implications of these intracellular events for the therapeutic activity and diagnostic capabilities of targeted agents.",
author = "E. Kluza and G.J. Strijkers and R.G.H. Beets-Tan and K. Nicolay",
year = "2013",
month = "7",
day = "1",
doi = "10.1007/978-1-4614-7876-8_18",
language = "English",
isbn = "978-1-4614-7875-1",
pages = "461--507",
editor = "Bae, {You Han} and Mrsny, {Randall J.} and Kinam Park",
booktitle = "Cancer Targeted Drug Delivery",
publisher = "Springer",
address = "Germany",

}

Kluza, E, Strijkers, GJ, Beets-Tan, RGH & Nicolay, K 2013, Cancer-specific ligand-receptor interactions. in YH Bae, RJ Mrsny & K Park (eds), Cancer Targeted Drug Delivery: An Elusive Dream. Springer, New York, pp. 461-507. https://doi.org/10.1007/978-1-4614-7876-8_18

Cancer-specific ligand-receptor interactions. / Kluza, E.; Strijkers, G.J.; Beets-Tan, R.G.H.; Nicolay, K.

Cancer Targeted Drug Delivery: An Elusive Dream. ed. / You Han Bae; Randall J. Mrsny; Kinam Park. New York : Springer, 2013. p. 461-507.

Research output: Chapter in Book/Report/Conference proceedingChapterAcademicpeer-review

TY - CHAP

T1 - Cancer-specific ligand-receptor interactions

AU - Kluza, E.

AU - Strijkers, G.J.

AU - Beets-Tan, R.G.H.

AU - Nicolay, K.

PY - 2013/7/1

Y1 - 2013/7/1

N2 - The concept of cancer targeting, which exploits the abundance of specific molecular epitopes on cancer cells, has been proposed as a strategy to enhance the efficacy and specificity of cancer therapy and diagnostics. Although many promising results have been obtained with this approach, the research experience of the last decades demonstrates clearly the challenges that the clinical application of cancer-targeted approaches faces. This can be attributed to both the complexity of targeted probe-cell interactions as well as the multitude of additional factors, which influence the efficacy of the targeting process. The aim of this chapter is to address the key steps involved in the cellular pathway of ligand-functionalized probes for cancer targeting. Special attention is given to nanoparticulate delivery systems as the most commonly exploited formulations for cancer targeting. Their interaction with target cells is initiated by ligand binding to the cell surface receptor, which is frequently followed by endocytosis of ligand-receptor complex and, in the final phase, by lysosomal degradation. All the aforementioned processes are presented in view of the pathophysiological and molecular features of the biological system as well as the physicochemical and biological properties of targeted probes. Importantly, we discuss the implications of these intracellular events for the therapeutic activity and diagnostic capabilities of targeted agents.

AB - The concept of cancer targeting, which exploits the abundance of specific molecular epitopes on cancer cells, has been proposed as a strategy to enhance the efficacy and specificity of cancer therapy and diagnostics. Although many promising results have been obtained with this approach, the research experience of the last decades demonstrates clearly the challenges that the clinical application of cancer-targeted approaches faces. This can be attributed to both the complexity of targeted probe-cell interactions as well as the multitude of additional factors, which influence the efficacy of the targeting process. The aim of this chapter is to address the key steps involved in the cellular pathway of ligand-functionalized probes for cancer targeting. Special attention is given to nanoparticulate delivery systems as the most commonly exploited formulations for cancer targeting. Their interaction with target cells is initiated by ligand binding to the cell surface receptor, which is frequently followed by endocytosis of ligand-receptor complex and, in the final phase, by lysosomal degradation. All the aforementioned processes are presented in view of the pathophysiological and molecular features of the biological system as well as the physicochemical and biological properties of targeted probes. Importantly, we discuss the implications of these intracellular events for the therapeutic activity and diagnostic capabilities of targeted agents.

UR - http://www.scopus.com/inward/record.url?scp=84929682883&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-7876-8_18

DO - 10.1007/978-1-4614-7876-8_18

M3 - Chapter

AN - SCOPUS:84929682883

SN - 978-1-4614-7875-1

SP - 461

EP - 507

BT - Cancer Targeted Drug Delivery

A2 - Bae, You Han

A2 - Mrsny, Randall J.

A2 - Park, Kinam

PB - Springer

CY - New York

ER -

Kluza E, Strijkers GJ, Beets-Tan RGH, Nicolay K. Cancer-specific ligand-receptor interactions. In Bae YH, Mrsny RJ, Park K, editors, Cancer Targeted Drug Delivery: An Elusive Dream. New York: Springer. 2013. p. 461-507 https://doi.org/10.1007/978-1-4614-7876-8_18